Back to Journals » Biologics: Targets and Therapy » Volume 4

New and emerging treatment approaches to lupus

Authors Haubitz M

Published 6 September 2010 Volume 2010:4 Pages 263—271

DOI https://doi.org/10.2147/BTT.S7581

Review by Single-blind

Peer reviewer comments 6

Marion Haubitz
Department of Nephrology, Medical School Hannover, Hanover, Germany
Abstract: The main goal in systemic lupus erythematosus (SLE) is to achieve remission, as this has a major impact on patient and renal survival. Furthermore, early treatment success has been shown to improve long-term prognosis. Treatment in severe SLE, especially in lupus nephritis, has traditionally been a standardized schematic therapy with cyclophosphamide and prednisolone followed by azathioprine. However, animal and human studies have increased our pathogenetic knowledge of this autoimmune disease with emerging new treatment targets. New and future therapeutic approaches are focused on B-cell depletion, T-cell downregulation and co-stimulatory blockade, cytokine inhibition, or the modulation of complement. Many different biological agents have been used in recent and ongoing studies, but up to now breakthroughs emerging from randomized Phase III trials have been rare. However, the future remains exciting with progress towards safe treatments with which to control the disease in the long run.
Keywords: systemic lupus erythematosus, lupus nephritis, B-cell depletion, co-stimulatory blockade, cytokine inhibition, monoclonal antibodies

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]